Substances_stimulants

Cocaine and Stimulant Addiction: Treatment and Recovery

By NJ Addiction Centers Editorial Team | Last reviewed: | 19 min read Clinically Reviewed

Stimulant addiction involves cocaine (powder and crack), methamphetamine, and prescription stimulants such as amphetamine/dextroamphetamine (Adderall) and methylphenidate (Ritalin). Unlike opioid use disorder, there are currently no FDA-approved medications for stimulant addiction — treatment relies primarily on behavioral interventions, structured programming, and in many cases, inpatient or residential care to break the use cycle. According to SAMHSA’s 2023 National Survey on Drug Use and Health, approximately 1.4 million Americans aged 12 or older had a cocaine use disorder in the past year, and approximately 1.0 million had a methamphetamine use disorder.

This guide covers how stimulant addiction develops, what treatment looks like in the absence of pharmacological tools, and what New Jersey residents should know about stimulant-specific treatment resources.

Key Takeaways

  • There are no FDA-approved medications for cocaine or methamphetamine addiction, making behavioral therapies the primary treatment approach
  • Contingency management, which provides tangible incentives for meeting treatment goals such as negative drug screens, has the strongest evidence base for stimulant use disorders according to NIDA
  • Stimulant withdrawal is not typically life-threatening but involves significant psychological symptoms including severe depression, fatigue, and intense cravings
  • Crack cocaine and powder cocaine are pharmacologically the same substance (cocaine hydrochloride vs. freebase cocaine) but differ in route of administration, onset of effects, and associated health risks
  • Prescription stimulant misuse, particularly among young adults, is a growing area of concern nationally
  • In New Jersey, cocaine remains involved in a significant proportion of polysubstance overdose deaths, often in combination with fentanyl

Understanding Stimulant Addiction

Stimulants increase activity in the central nervous system by elevating levels of dopamine, norepinephrine, and serotonin in the brain. Cocaine achieves this by blocking the reuptake of dopamine, causing a rapid surge that produces euphoria, increased energy, and heightened alertness. Methamphetamine has a similar mechanism but also triggers the direct release of dopamine, producing a longer-lasting and more intense effect.

The dopamine system is central to stimulant addiction. Repeated stimulant use alters the brain’s reward circuitry, reducing the number and sensitivity of dopamine receptors over time. This means that activities that once produced pleasure — food, social interaction, exercise — become less rewarding, while the drive to use stimulants intensifies. This neuroadaptation is what transforms recreational use into compulsive use.

Speed of onset matters. Routes of administration that deliver the drug to the brain faster — smoking and injection — carry a higher addiction risk than routes with slower onset, such as snorting. This is why crack cocaine (smoked, reaching the brain in seconds) is associated with faster development of dependence than powder cocaine (snorted, reaching the brain in minutes).

Binge patterns. Stimulant addiction commonly involves binge use — periods of repeated, escalating doses over hours or days, followed by a “crash” of exhaustion, depression, and sleep. This binge-crash cycle is characteristic of both cocaine and methamphetamine use and differs from the more continuous use patterns seen with opioids or alcohol.

According to CDC data, psychostimulant-involved overdose deaths have risen sharply over the past decade, increasing from approximately 5,500 in 2015 to over 34,000 in 2023 — driven primarily by methamphetamine. In many cases, stimulant-involved deaths also involve opioids, reflecting the reality of polysubstance use.

Signs and Symptoms of Cocaine Addiction

Cocaine use disorder is defined in the DSM-5 by the same 11-criteria framework used for all substance use disorders, but several behavioral and physical patterns are particularly characteristic of cocaine addiction.

Behavioral indicators:

  • Periods of unusual energy, talkativeness, and confidence followed by crashes of depression and withdrawal
  • Financial problems inconsistent with income — cocaine is expensive, and heavy use can consume thousands of dollars per week
  • Secretive behavior, frequent disappearances, and unreliability
  • Changes in social circle, particularly gravitating toward other users
  • Neglect of responsibilities at work, school, or home during and after binges

Physical indicators:

  • Chronic nasal problems — runny nose, nosebleeds, loss of smell, perforated septum (with snorted cocaine)
  • Dilated pupils, especially at inappropriate times
  • Significant weight loss and decreased appetite
  • Insomnia during use followed by extended sleep during the crash phase
  • Track marks (if injecting), burns on lips or fingers (if smoking crack)

Psychological indicators:

  • Paranoia and suspiciousness, particularly during or after heavy use
  • Irritability and agitation during periods without cocaine
  • Anxiety and panic attacks
  • In severe cases, cocaine-induced psychosis — hallucinations, delusions, and extreme paranoia

One of the defining characteristics of cocaine addiction is the intensity of cravings. Environmental cues — people, places, and paraphernalia associated with use — can trigger powerful urges even after extended periods of abstinence. This cue-induced craving is one reason that behavioral therapies addressing cognitive patterns and environmental management are central to treatment.

For a more detailed examination of the signs of cocaine addiction and when use crosses from recreational to disordered, see cocaine addiction signs.

Cocaine Addiction Treatment Options

The absence of FDA-approved medications for stimulant use disorders means that treatment relies on behavioral and psychosocial interventions. This is a meaningful limitation — for opioid use disorder, medications like buprenorphine and methadone dramatically improve outcomes, and no equivalent tool exists for cocaine or methamphetamine.

Behavioral Therapies

Contingency management (CM): Research conducted by NIDA and published in journals including the Journal of Substance Abuse Treatment and Drug and Alcohol Dependence consistently shows contingency management as the most effective behavioral intervention for stimulant use disorders. CM provides tangible incentives — vouchers, prizes, or cash equivalents — for achieving treatment goals, primarily negative drug screens. The VA has implemented contingency management programs nationally for stimulant use disorder treatment, and the California Department of Health Care Services launched a Medicaid-funded contingency management pilot in 2024.

Cognitive Behavioral Therapy (CBT): CBT helps patients identify thought patterns and situations that trigger cocaine use and develop alternative coping strategies. CBT is well-studied for substance use disorders generally, and its application to stimulant addiction focuses heavily on managing cravings, avoiding high-risk situations, and building a recovery routine.

The Matrix Model: A structured outpatient treatment approach developed specifically for stimulant addiction. The Matrix Model combines CBT, family education, individual counseling, 12-step facilitation, drug testing, and relapse prevention over a 16-week period. NIDA-funded research has supported its effectiveness for methamphetamine and cocaine use disorders.

Community Reinforcement Approach (CRA): CRA restructures the patient’s environment so that non-drug activities become more rewarding than drug use. It addresses social relationships, vocational skills, and recreational activities — aiming to make a sober life more reinforcing than continued stimulant use.

Levels of Care

Stimulant addiction is treated across all ASAM levels of care, but the binge-crash cycle and the intensity of cravings often support an initial period of residential or inpatient treatment to break the pattern. After stabilization, step-down to IOP or outpatient care with ongoing drug screening is a common treatment trajectory.

For detailed guidance on treatment approaches specific to cocaine, including program structures and what to look for in NJ, see cocaine treatment options and cocaine addiction help.

Crack Cocaine: Unique Treatment Considerations

Crack cocaine is the freebase form of cocaine, processed to be smoked rather than snorted or injected. Pharmacologically, crack and powder cocaine are the same active compound — benzoylmethylecgonine. The difference is in the route of administration and the speed of onset.

Pharmacological distinction: When crack is smoked, cocaine reaches the brain in approximately 8 to 10 seconds, producing a rapid, intense, but short-lived high lasting 5 to 15 minutes. Powder cocaine, when snorted, reaches the brain in approximately 3 to 5 minutes, producing a less intense but longer-lasting effect of 15 to 30 minutes. The speed and intensity of crack’s onset is what makes it associated with faster development of compulsive use.

Treatment considerations specific to crack:

  • The rapid onset and short duration create a tighter binge cycle — users may smoke repeatedly within a session, driving escalation
  • Crack use is more commonly associated with homelessness, poverty, and involvement with the criminal justice system than powder cocaine use, which affects treatment access and recovery environment
  • Crack-related health complications include respiratory damage from smoking, burns, and a higher risk of cardiovascular events due to the rapid delivery of large doses
  • The historical sentencing disparity between crack and powder cocaine (largely addressed by the Fair Sentencing Act of 2010 and the First Step Act of 2018) created collateral consequences — criminal records, housing barriers — that continue to affect individuals in recovery

Treatment approach: The clinical treatment for crack cocaine addiction is the same as for powder cocaine addiction — behavioral therapies, contingency management, structured programming, and environmental change. However, the social determinants associated with crack use often require additional wraparound services, including housing support, employment assistance, and legal aid.

For a comprehensive examination of crack cocaine addiction, including demographics, health effects, and treatment pathways, see crack cocaine addiction.

Cocaine Withdrawal: What to Expect

Cocaine withdrawal differs fundamentally from opioid or alcohol withdrawal. It does not involve the acute physical symptoms — vomiting, seizures, tremors — associated with those substances. However, cocaine withdrawal is marked by significant psychological distress that can drive relapse.

Withdrawal timeline:

Crash phase (hours to days after last use): Extreme fatigue, increased sleep (sometimes 12-18 hours), depressed mood, increased appetite, irritability. This phase is the body’s response to dopamine depletion after sustained stimulant use.

Acute withdrawal (1 to 3 weeks): Persistent depressed mood, anhedonia (inability to experience pleasure from normally enjoyable activities), low energy, disturbed sleep, vivid and unpleasant dreams, difficulty concentrating. Cravings fluctuate but can be intense, especially in response to environmental cues.

Extended withdrawal (weeks to months): Gradually improving mood and energy, but intermittent cravings — sometimes triggered unexpectedly — may persist for months. Anhedonia can be particularly persistent as the dopamine system slowly recalibrates.

Medical considerations: While cocaine withdrawal is not typically medically dangerous, the depression that accompanies it can be severe. Suicidal ideation is a documented risk during cocaine withdrawal, particularly in individuals with pre-existing mood disorders. Medical monitoring during the crash and acute withdrawal phases is appropriate, especially for heavy or long-duration users.

No FDA-approved withdrawal medications: Unlike opioid withdrawal (which can be managed with buprenorphine, methadone, or clonidine), there are no FDA-approved medications specifically for cocaine withdrawal. Some clinicians use off-label approaches — modafinil, topiramate, or N-acetylcysteine have been studied in clinical trials — but none have achieved FDA approval for this indication, and evidence remains mixed.

For a detailed breakdown of the cocaine withdrawal timeline, symptom management strategies, and when medical supervision is warranted, see cocaine withdrawal.

Methamphetamine and Prescription Stimulant Misuse

While cocaine remains the primary stimulant of concern in the Northeast, methamphetamine use has been increasing in New Jersey and other Eastern states over the past decade, and prescription stimulant misuse has become a growing concern nationally.

Methamphetamine: Methamphetamine produces a longer-lasting high than cocaine (up to 12 hours versus cocaine’s 15-60 minutes depending on route). Chronic methamphetamine use causes significant neurotoxic effects, including damage to dopamine and serotonin neurons. According to the CDC, methamphetamine-involved overdose deaths quadrupled nationally between 2015 and 2023. In New Jersey, methamphetamine has been less prevalent than in Western states, but DEA seizure data show increasing availability in the Northeast.

Prescription stimulant misuse: Medications such as Adderall (amphetamine/dextroamphetamine), Ritalin (methylphenidate), and Vyvanse (lisdexamfetamine) are FDA-approved for ADHD and are among the most commonly prescribed controlled substances in the United States. According to SAMHSA’s 2023 NSDUH, approximately 3.7 million people aged 12 or older misused prescription stimulants in the past year. Misuse is most prevalent among young adults aged 18-25, often in academic or professional settings.

Treatment approach: Treatment for methamphetamine and prescription stimulant addiction follows the same general framework as cocaine treatment — behavioral therapies (particularly contingency management and CBT), structured programming, and environmental support. Methamphetamine withdrawal tends to involve more prolonged anhedonia and cognitive impairment than cocaine withdrawal, and recovery of dopamine system function may take longer.

Cross-Addiction and Transfer Addiction

Individuals in recovery from stimulant addiction face an elevated risk of developing dependence on other substances — a phenomenon variously called cross-addiction, transfer addiction, or addiction transfer. This is not a moral failing but a neurobiological reality rooted in the same reward system dysfunction that drove the initial addiction.

Common patterns:

  • Substituting alcohol for cocaine, especially in social settings where cocaine was previously used
  • Developing opioid dependence, sometimes initiated through prescription painkillers encountered during medical treatment
  • Escalating cannabis or benzodiazepine use to manage the anxiety and insomnia that persist during stimulant recovery
  • Behavioral addictions — gambling, compulsive spending, disordered eating — emerging as alternative sources of dopamine stimulation

Integrated treatment approach: Quality treatment programs screen for polysubstance use and address the underlying reward system dysfunction rather than treating a single substance in isolation. Aftercare planning should include ongoing monitoring for new substance use and behavioral addiction patterns.

The reality of polysubstance use is particularly relevant to the overdose crisis. In New Jersey, a significant number of cocaine-involved deaths also involve fentanyl — individuals using cocaine may be unknowingly exposed to fentanyl through contaminated supply, or may intentionally combine the two (a combination known as a “speedball” when cocaine is combined with heroin or fentanyl).

For more on the risks of substituting one substance for another and how integrated treatment addresses polysubstance vulnerability, see replacing one addiction with another.

Contingency Management: The Most Effective Stimulant Treatment Most Programs Don’t Offer

If there is one unambiguous gap between the evidence base and common clinical practice in NJ stimulant treatment, it is the under-use of contingency management. The research case for CM as the most effective stimulant treatment intervention is as strong as any evidence base in addiction medicine — yet a significant share of NJ programs treating cocaine and methamphetamine use disorder do not offer it. This section explains what CM is, why it works, why it’s hard to find, and how to evaluate whether a program is actually providing it.

What contingency management is. CM provides tangible incentives — vouchers, prizes, cash equivalents, or earned privileges — contingent on specific, verifiable behavior, most commonly negative urine drug screens. The incentives are typically modest (starting around $10 for the first negative screen, escalating with successive negatives and resetting on a positive) and are delivered on a predictable schedule that reinforces the behavior without creating a system that can be gamed.

Why CM works for stimulants specifically. Stimulant use hijacks the brain’s reward system — the dopamine system that evolved to reinforce survival behavior. Cognitive therapies like CBT help patients understand and modify thinking, but stimulant craving is not primarily a cognitive problem. It’s a reward-system problem. CM works by doing the one thing that can compete directly with stimulant reinforcement: providing an alternative, externally-delivered reward for the alternative behavior (not using). Over weeks and months of CM, patients build habit strength around being sober, and the external reinforcement can gradually taper.

The evidence. Multiple Cochrane reviews and meta-analyses have shown that CM produces substantially greater reductions in stimulant use than any other intervention. A 2021 meta-analysis in JAMA Psychiatry found CM produced roughly twice the rate of end-of-treatment abstinence compared to CBT alone for stimulant use disorder. NIDA has issued repeated guidance that CM should be a standard of care for stimulant use disorder. The Department of Veterans Affairs has broadly implemented CM across its addiction-treatment network; outside the VA, adoption has been slower.

Why CM is hard to find in NJ. Three barriers:

  1. Reimbursement. Insurance plans — including Medicaid — have historically not paid for the incentive component of CM. A program offering CM typically has to pay for the incentives out of other funds (grants, philanthropic support, research funding). That’s a structural disincentive for most programs to offer it, regardless of the evidence.
  2. Perceived cultural mismatch. CM can strike some clinicians and funders as “paying people to not use drugs” — which sounds wrong even though the clinical outcomes are strong. This is a framing issue, not a clinical one, but it has slowed adoption.
  3. Operational complexity. Running CM well requires systematic drug testing, reliable incentive tracking, and a specific clinical workflow. Programs without that infrastructure can’t easily bolt it on.

Where CM is available in NJ. The NJ VA system (VA New Jersey Health Care System) has CM programs as part of its substance use treatment. Several academic medical centers in NJ have CM components within research-funded programs — Rutgers, Rowan, and similar programs offer CM through specific study enrollments. A small number of NJ community programs have integrated CM, often grant-funded through DMHAS or opioid settlement allocations. The landscape is changing; opioid settlement funds are increasingly being directed toward CM for stimulant use disorder given its evidence base.

How to evaluate whether a program actually offers CM. The key questions:

  • Do you offer contingency management, and if so, in what form?
  • What are the specific incentives, and what is the magnitude?
  • How do you verify the target behavior (urine testing, breathalyzer, observed dosing)?
  • Is CM continued throughout treatment or only during an initial phase?
  • Who pays for the incentives — insurance, grant funding, program operating budget?

A program that describes “contingency-based reinforcement” but offers only praise, certificates, or tokens is not providing CM at the level supported by the evidence. The incentives need to be tangible and meaningful.

Second-line interventions for stimulants. When CM is not accessible, the next-best evidence base is behavioral: CBT (particularly the Matrix Model, a structured 16-week outpatient program), motivational enhancement therapy, and mindfulness-based relapse prevention. Emerging pharmacotherapy research — including the bupropion + extended-release naltrexone combination studied in NEJM for methamphetamine use disorder — may provide additional tools in the coming years. For now, CM + behavioral + (when appropriate) pharmacotherapy remains the strongest combination.

Fentanyl-Adulterated Cocaine and the New Polysubstance Overdose Profile

Over the past 5 years, one of the most clinically significant shifts in NJ’s stimulant use landscape has been the contamination of cocaine (and methamphetamine) supply with fentanyl. This is not theoretical — it’s reflected in NJ overdose data. A substantial and growing fraction of NJ overdose deaths now involve both stimulants and fentanyl, with CDC and NJ DOH SUDORS data showing psychostimulants involved in roughly one-third of nationwide overdose deaths, most commonly in combination with synthetic opioids. For people who use stimulants and believe they are not at opioid overdose risk, the clinical picture has changed.

How fentanyl ends up in cocaine. The pathways are both deliberate (some dealers intentionally add fentanyl to stimulants to intensify effects or create dependence) and accidental (cross-contamination in production and packaging). Testing programs — including at NJ SAP sites — have detected fentanyl in cocaine samples at variable rates; the contamination is geographically and temporally inconsistent, which is itself dangerous because a user’s “regular supply” can change without warning.

The clinical overdose profile is different. A combined stimulant/fentanyl overdose can present in ways that aren’t typical of either substance alone — sympathomimetic effects (elevated heart rate, agitation, hyperthermia) from the stimulant combined with respiratory depression from the fentanyl. Bystanders looking for classic “opioid overdose” signs (slowed breathing, pinpoint pupils, unresponsiveness) may miss the presentation initially because the stimulant effects mask some of the opioid signs. By the time respiratory depression is obvious, the window for naloxone response is narrower.

Why stimulant users need naloxone now. Any person using cocaine or methamphetamine in NJ should have access to naloxone, should carry it when using, and should be with someone trained to use it. This is a harm reduction change in stance — not long ago, stimulant users were not considered at meaningful opioid overdose risk. The contamination of supply has made that assumption dangerous.

Fentanyl test strips — the NJ access story. Fentanyl test strips allow rapid testing of drug residue for fentanyl presence. In most NJ jurisdictions, these strips are legal and distributed through NJ Syringe Access Programs, harm reduction organizations, and some treatment programs. (Paraphernalia laws have historically complicated distribution; NJ has been among the states moving to explicitly exempt fentanyl test strips from paraphernalia statutes.) A test strip result is imperfect — a negative result doesn’t guarantee a sample is fentanyl-free because contamination can be unevenly distributed — but it is substantially better than no testing. Anyone using stimulants in NJ should have access to test strips as part of their harm reduction setup.

Implications for treatment programs. NJ stimulant treatment programs are increasingly integrating:

  • Naloxone distribution and training as part of admission protocols for stimulant-use patients
  • Fentanyl test strip access
  • Screening for opioid use (including accidental exposure) during stimulant-primary treatment
  • MAT consideration if assessment reveals OUD in addition to StUD

Programs that treat stimulant use disorder in isolation from opioid risk are not reflecting the current NJ substance landscape.

The xylazine factor. Compounding the fentanyl issue, xylazine (the veterinary sedative, “tranq”) has appeared in NJ drug samples including some labeled as cocaine or powder. Xylazine is not reversed by naloxone, produces its own withdrawal syndrome, and is associated with severe necrotic skin wounds. Treatment programs serving stimulant-use patients in NJ should have awareness of xylazine presentation and wound-care protocols, even if the primary presenting substance is cocaine or methamphetamine.

Harm reduction as part of treatment, not separate from it. A common conceptual error is treating harm reduction and abstinence-focused treatment as opposing approaches. In the NJ stimulant landscape in 2026, they are complementary: harm reduction keeps patients alive long enough to engage with treatment when they are ready, and treatment provides the infrastructure for long-term change. A stimulant treatment program that does not provide naloxone, test strips, or overdose education is operating as if the drug supply hasn’t changed. It has.

New Jersey’s substance use landscape has been dominated by the opioid crisis, but stimulant use remains a significant and evolving concern.

According to the NJ Department of Health and the NJ State Police Uniform Crime Report, cocaine continues to be widely available throughout the state. NJ SUDORS data show cocaine present in a substantial proportion of polysubstance overdose deaths, frequently in combination with fentanyl. The contamination of the cocaine supply with fentanyl is a particular concern — users who believe they are using only cocaine may be unknowingly exposed to a potent synthetic opioid.

NJ treatment admission data from DMHAS show that cocaine-related admissions have remained relatively stable over the past several years, even as opioid-related admissions have fluctuated. This suggests a persistent baseline of cocaine use disorder in the state that has not been displaced by the opioid epidemic.

For stimulant-specific treatment in New Jersey, SAMHSA’s treatment locator (findtreatment.gov) allows filtering by substance type. NJ residents can also call the state’s addiction services hotline at 1-844-276-2777 for referrals to programs that address cocaine and stimulant use disorders specifically.

Topics in This Guide

For foundational information on how addiction develops and how the brain’s reward system is affected by substance use, see our guide to understanding addiction. For an overview of the treatment modalities referenced throughout this page — including CBT, contingency management, and inpatient programs — see types of addiction treatment.

Looking for treatment options in your area? We can help point you in the right direction. (888) 699-0742 — or request a callback.